[NEWSMP] As the medical supplies index rose sharply, exceeding the 16,000 mark for the first time in nearly two years, the combined market capitalization of 47 constituent stocks also surpassed 150 trillion won.
In particular, 12 of the 47 constituents of the medical supplies index gained more than 10% during the month of August.
According to the Korea Exchange, 25 stocks, more than half of the 47 components of the medical supplies index, experienced declines in stock prices in August.
On the other hand, 20 stocks saw an increase in stock prices, which was fewer than those that declined, and 12 stocks recorded double-digit gains, accounting for more than half of the gains.
Moreover, 17 out of the 20 stocks that saw gains in prices, rose by more than 5%. In contrast, 12 stocks fell by more than 5%, and only 3 stocks experienced double-digit declines.
The highest gainer during the period was Yuhan Corporation, which surged 49.4%, followed by Chong Kun Dang Bio, which increased by 35.2%.
GC Biopharma and Daewoong Pharmaceutical also surpassed 20%, rising by 27.8% and 20.4%, respectively, while Daewoong recorded nearly double-digit growth of 19.3%.
Additionally, Bionote, Boryung, Hanall Biopharma, Samil Pharmaceutical, Shinpoong Pharmaceutical, Pharmicell, and Chong Kun Dang also posted double-digit growth.
Chong Kun Dang Holdings, Hanmi Pharmaceutical, Ildong Pharmaceutical, Ildong Holdings, and Dong-A ST, also rose by more than 5%, while Samsung Biologics, Il-Yang Pharmaceutical, and Jeil Pharmaceutical saw slight increases.
During the same period, three stocks—Hyundai Pharmaceutical, GeneOne Life Science, and Kukje Pharma—suffered double-digit declines. Kwang Dong Pharmaceutical, Aprogen Pharmaceuticals, Orient Bio, JW Pharmaceutical, Hana Pharm, Dongsung Bio Pharm, Handok, Whanin Pharmaceutical, and Myungmoon Pharm also fell by more than 5%.
In addition, Daewon Pharmaceutical, PharmGen Science, Dong Wha Pharmaceuticals, Bukwang Pharmaceutical, Samjin Pharmaceutical, JW Life Science, Ilsung IS, Korea United Pharm, Youngjin Pharm, Yuyu Pharma, Celltrion, Reyon Pharmaceutical, and Samsung Pharmaceutical saw declines compared to the end of July, while SK Bioscience and KyongBo Pharmaceutical remained flat.
The combined market cap of the 47 medical supplies index constituents increased by 8.35 trillion won from 144.58 trillion won to 152.93 trillion won, surpassing the 150 trillion won mark, driven by the double-digit gains of 12 stocks, including Yuhan Corporation, which soared nearly 50%.
In particular, Yuhan Corporation's market cap surged by 3.74 trillion won, surpassing the 10 trillion won mark, while Samsung Biologics also expanded by nearly 3 trillion won.
Additionally, the market cap of eight stocks increased by more than 100 billion won, including GC Biopharma with 434.7 billion won, Hanmi Pharmaceutical with 339.5 billion won, Daewoong Pharmaceutical with 294.3 billion won, Hanall Biopharma with 242.9 billion won, Daewoong with 241.3 billion won and Chong Kun Dang with 170 billion won.
Celltrion, on the other hand, was the only stock to see a market cap decline of more than 1 trillion won over the same period, losing 391.8 billion won.
As of the end of August, Samsung Biologics had the largest market cap of 69.75 trillion won, followed by Celltrion with 44.05 trillion won.
Yuhan Corporation surpassed the 10 trillion won mark with 11.31 trillion won. SK Bioscience maintained its position at 4.26 trillion won, while Hanmi Pharmaceutical returned to the 4 trillion won range with 4.04 trillion won.
Hanall Biopharma also surpassed the 2 trillion won mark with 2.09 trillion won, while other companies such as GC BioPharma, Daewoong Pharmaceutical, Chong Kun Dang, and Daewoong maintained market caps in the 1 trillion won range.
